FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Its two small-molecule candidates are cleared for Phase 1 trials in the US and Europe, and it passed the KOSDAQ technology evaluation.

  • Announced A and A grades in its KOSDAQ technology evaluation. Source
  • Announced European Phase 1 approval for CV-01. Source

Roles often seen at this stageClinical & PV · Research & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

CUREVERSE

Develops small-molecule drugs for brain diseases and granted Italy's Angelini Pharma a global license option on its candidate CV-01.

CV-01

Phase 1

Candidate aimed at drug-resistant epilepsy and other conditions; partner Angelini Pharma received approval in Sweden in June 2026 for a 36-person Phase 1 trial.

CV-02

Phase 1

Small-molecule candidate acting selectively on the S1P1 receptor; cleared by the US FDA for a Phase 1 trial in 64 healthy adults.

Completion reported

Received A and A grades from two agencies in its KOSDAQ technology evaluation.

Completion reported

A Phase 1 trial of CV-01 was approved in Sweden.

Official role guide

CUREVERSE careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 큐어버스 CV-02 미국 FDA 임상 1상 승인 ↗전자신문 · Published 2025-06-09 · Sources checked 2026-11-18 · Original unavailable
  2. 큐어버스 CV-01 유럽 임상 1상 승인 ↗큐어버스 · Published 2026-07-24 · Sources checked 2026-11-18 · Original unavailable
  3. 큐어버스 코스닥 기술성 평가 통과 ↗큐어버스 · Published 2026-09-30 · Sources checked 2026-11-18 · Original unavailable
  4. 인재채용 ↗큐어버스 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable